Guluronic acid sodium

Synonyms: G2013 sodium
Guluronic acid sodium (G2013) 是一种口服有效的氧化应激调节剂与抗炎剂,能通过下调 TLR4、NF-κB、iNOS 等多种促炎及氧化应激相关基因并抑制 COX-2、MMPs 及 VEGF 的活性来发挥药理作用,低剂量时可上调免疫调节基因 SHIP1 和 SOCS1 的表达,从而有效抑制癌症相关炎症、肿瘤血管生成、细胞黏附及转移,同时减少免疫抑制细胞的聚集,并在无直接细胞毒性的浓度范围内显著延长荷瘤宿主的生存期,展现出良好的安全性,可用于多发性硬化、强直性脊柱炎、乳腺癌及其他炎症性疾病的研究。
Guluronic acid sodium
产品编号: MS-Z31754 纯度: 98.0% 分子式: C6H9NaO7 分子量: 216.12
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Guluronic acid sodium (G2013) 是一种口服有效的氧化应激调节剂与抗炎剂,能通过下调 TLR4、NF-κB、iNOS 等多种促炎及氧化应激相关基因并抑制 COX-2、MMPs 及 VEGF 的活性来发挥药理作用,低剂量时可上调免疫调节基因 SHIP1 和 SOCS1 的表达,从而有效抑制癌症相关炎症、肿瘤血管生成、细胞黏附及转移,同时减少免疫抑制细胞的聚集,并在无直接细胞毒性的浓度范围内显著延长荷瘤宿主的生存期,展现出良好的安全性,可用于多发性硬化、强直性脊柱炎、乳腺癌及其他炎症性疾病的研究。

生物实验数据

生物活性 Guluronic acid sodium (G2013) is an orally effective oxidative stress modulator and anti-inflammatory agent that exerts its pharmacological effects by downregulating multiple pro-inflammatory and oxidative stress-related genes such as TLR4, NF-κB, and iNOS and inhibiting the activities of COX-2, MMPs, and VEGF; at low doses, it upregulates the expression of the immunomodulatory genes SHIP1 and SOCS1, thereby effectively suppressing cancer-related inflammation, tumor angiogenesis, cell adhesion, and metastasis while reducing the accumulation of immunosuppressive cells, and within a concentration range without direct cytotoxicity, it significantly prolongs the survival of tumor-bearing hosts, demonstrating a favorable safety profile, and it is used in research on multiple sclerosis, ankylosing spondylitis, breast cancer, and other inflammatory diseases.
IC50 & Target

MMP-9

 

MMP-2

 

COX-2

 

TLR4

 

iNOS

 

体外研究
(In Vitro)

Guluronic acid sodium (G2013) (25 μg/well;LPS 预孵育 4 h 后处理 18 h) 可显著抑制 LPS 诱导的健康人外周血单个核细胞 (PBMCs) 中 SOD2、GPX1、GST 及 MPO 的 mRNA 表达;显著抑制 LPS 诱导的上述细胞中 CAT 和 iNOS 的 mRNA 表达。
Guluronic acid sodium (5 μg/well;24 h) 显著下调 TLR4、MyD88 和 NF-κB 的基因表达,并显著上调 SHIP1 和 SOCS1 的基因表达。
Guluronic acid sodium (25-500 ng/mL;24 h, 48 h) 对 HEK-Blue hTLR4 细胞的 24 h IC50 为 125 μg/ml,对 4T1 小鼠乳腺癌细胞的增殖无显著影响。
Guluronic acid sodium (25-500 μg/ml;48 h) 剂量依赖性地抑制 4T1 小鼠乳腺癌细胞中 MMP2 (活性降低 22-31%) 和 MMP9 (活性降低 28-44%) 的活性。
Guluronic acid sodium (25-500 μg/ml;共孵育 24 h) 可使 J774 小鼠巨噬细胞中 LPS 诱导的 PG2E 生成量降低约 66%。

Cell Cytotoxicity Assay

Cell Line: HEK-Blue hTLR4 cells
Concentration: 200 ng/ml, 1 μg/ml, 5 μg/ml, 25 μg/ml, 125 μg/ml
Incubation Time: 24 h
Result: Showed no cytotoxic effect at concentrations below 125 μg/ml. Reduced cell viability to ~60% of the control at 125 μg/ml. Reached an IC50 of 125 μg/ml after 24 h treatment.

Real Time qPCR

Cell Line: HEK-Blue hTLR4 cells (untreated condition)
Concentration: 5 μg/well (low dose); 15 μg/well (high dose)
Incubation Time: 24 h
Result: Decreased TLR4 gene expression by 65% (low dose) and 41% (high dose), compared to control.
Decreased MyD88 gene expression by 82% (low dose) and 47% (high dose), compared to control.
Increased SHIP1 gene expression by 62% (low dose) and decreased it by 27% (high dose, non-significant), compared to control. Increased SOCS1 gene expression by 72% (low dose) and decreased it by 29% (high dose), compared to control.
Decreased NF-κB gene expression by 69% (low dose) and 49% (high dose, non-significant), compared to control.

ELISA Assay

Cell Line: J774 murine macrophage cells
Concentration: 25, 250, 500 μg/ml
Incubation Time: 24 h (co-incubated with LPS)
Result: Reduced PGE2 levels by ~66% across all tested concentrations compared to LPS-only treated cells.
体内研究
(In Vivo)

Guluronic acid (G2013) sodium 可降低小鼠实验性自身免疫性脑脊髓炎的疾病严重程度、延缓发病并降低发病率。
Guluronic acid (50 mg/kg;腹腔注射;每 2 天 1 次;肿瘤接种后第 6 天至第 26 天) sodium 以及 Guluronic acid (50 μg/ml;对 4T1 细胞进行体外 48 小时预处理后造模) sodium 可抑制癌症相关炎症,将肿瘤生长抑制率最高提升至约 94.1%,消除经预处理细胞的转移能力,并延长同基因小鼠乳腺癌模型的生存期。

Animal Model: Breast cancer model in BALB/c (female, 6-8 weeks old, 18-20 g, syngeneic breast cancer model induced by 5×105 4T1 cell injection into mammary fat pad)
Dosage: 50 mg/kg (therapeutic group); 50 μg/ml (cell line pre-treated group)
Administration: i.p.; every 2 days; day 6 to day 26 post-tumor inoculation (therapeutic group); in vitro pre-treatment of 4T1 cells before inoculation (cell line pre-treated group)
Result: Reduced tumor volume by ~61.4% (therapeutic group) and ~94.1% (cell line pre-treated group) on day 30 post-inoculation compared to controls.
Exhibited metastasis incidence of 80% lung, 60% lymph node, and 20% liver (therapeutic group); showed no detectable metastasis in any organs (cell line pre-treated group).
Reduced lung metastatic area to ~5% per section (therapeutic group) and 0% (cell line pre-treated group) compared to ~15% in controls.
Lowered serum levels of IL-1β and IL-6 significantly in both groups; left TNF-α levels unchanged.
Reduced white blood cell count and granulocyte-to-lymphocyte ratio in both groups.
Reduced frequency of regulatory T cells (Treg) significantly in tumor tissue and lymph nodes (therapeutic group).
Reduced myeloid-derived suppressor cells (MDSC) significantly in tumor tissue and spleen (therapeutic group).
Reduced tumor angiogenesis by ~59.8% (therapeutic group) and ~91.1% (cell line pre-treated group) compared to controls.
Lowered tumor tissue mRNA expression of COX-2, MMP2, MMP9, and VEGF significantly in both groups compared to controls.
Prolonged survival significantly, with 100% of mice in the cell line pre-treated group surviving up to day 90, and higher survival rate in the therapeutic group than in controls.
性状 固体
颜色 White to light yellow

化学信息

分子量 216.12
分子式 C6H9NaO7
别名 G2013 sodium

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 62.5 mg/mL (289.19 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM4.6271 mL23.1353 mL46.2706 mL115.6765 mL
5 mM0.9254 mL4.6271 mL9.2541 mL23.1353 mL
10 mM0.4627 mL2.3135 mL4.6271 mL11.5676 mL
15 mM0.3085 mL1.5424 mL3.0847 mL7.7118 mL
20 mM0.2314 mL1.1568 mL2.3135 mL5.7838 mL
25 mM0.1851 mL0.9254 mL1.8508 mL4.6271 mL
30 mM0.1542 mL0.7712 mL1.5424 mL3.8559 mL
40 mM0.1157 mL0.5784 mL1.1568 mL2.8919 mL
50 mM0.0925 mL0.4627 mL0.9254 mL2.3135 mL
60 mM0.0771 mL0.3856 mL0.7712 mL1.9279 mL
80 mM0.0578 mL0.2892 mL0.5784 mL1.4460 mL
100 mM0.0463 mL0.2314 mL0.4627 mL1.1568 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础